LAB901 Partners with South Korean PCR Diagnostics Firm, Seegene Inc.
News May 22, 2008
Under the deal, Lab901 has appointed Seegene as its exclusive diagnostics distributor for the ScreenTape® system in the Korean market. The parties will also co-market their ScreenTape® and Seeplex® products in the global multiplex PCR diagnostics market.
Richard Rowling, Lab901’s Director of Sales & Marketing said “Lab901 is delighted to have secured this deal with Seegene. Combining Seegene’s highly multiplexed PCR diagnostic kits with Lab901’s simple and convenient automated analysis instrument will bring a great boost to both companies’ global sales”
Joel Fearnley, Co-founder and Chief Executive Officer of Lab901, commented “We are very excited about working with Seegene. The combination of their excellent multi-pathogen PCR tests with the simplicity, speed and sample traceability of the ScreenTape® system will be of real value to diagnostic microbiology and virology laboratories.”
“We are delighted to be working with Lab901 and we believe that their ScreenTape system will offer our global customer base a higher level of automation and standardisation.” commented Dr. Jong-Yoon Chun, Founder and Chief Executive Officer of Seegene.
Seegene’s Seeplex® tests are based on a multiplexing PCR technology capable of detecting multiple pathogens in a single tube. Currently, Seeplex® tests offer laboratories worldwide a comprehensive screening for Sexually Transmitted Diseases (STDs), respiratory viruses’, sepsis, human papillomavirus (HPV) and pneumonia.
In treating inflammatory bowel disease (IBD), physicians can have a hard time telling which newly diagnosed patients have a high risk of severe inflammation or what therapies will be most effective. Now researchers report finding an epigenetic signature in patient cells that appears to predict inflammation risk in a serious type of IBD called Crohn’s disease.